America's Back Office (ABO)’s Post

From the attention on GLP-1 drug coverage and the end of the COVID-19 emergencies to big pay raises and greater pay communication, here’s a look at some of the top total rewards trends this year.

Morphine Equivalent Dose (MED) is an important comparison when opioids are prescribed in #workcomp. Want to know more about how MED determines the potency of an opioid? Watch the video.

Employers, are you strategizing to achieve an ROI for the spend on GLP-1 medications? It's crucial to consider the following: - In the U.S., the number of individuals using GLP-1s is expected to surpass 30 million by 2030. - Global studies indicate that the market for GLP-1s is projected to surpass $471 billion by 2032. - To ensure optimal health and financial outcomes, incorporating lifestyle modifications into a GLP-1 strategy for personalized treatment is essential. Employers may consider integrating a vendor lifestyle modification program, although the effectiveness of specific vendor programs is still under evaluation. #Employers #GLP1Medications #HealthcareStrategy #ROI #LifestyleModification #VendorPrograms

Are your employees struggling to see results with GLP-1s for weight loss? As the buzz around these medications continues, questions persist. Why aren't some individuals shedding pounds as expected? The answer might lie in personalized guidance from a pharmacist. Dr. Jessica W. Lea, Pharm D, explains why pharmacists are essential in optimizing weight loss strategies. Discover how they can address individual factors hindering success and provide comprehensive support for sustainable results. Read more here: https://lnkd.in/g2JXa9cy #WeightLoss #GLP1s #PharmacistExpertise

Hot Topic among employers, GLP1's. If you're looking for the pro's and con's to weigh your options, we have you covered. Let me know if you register! I am curious to see how many groups are taking advantage of this informative webinar! Join us next Wednesday, February 7th to weigh your options. https://lnkd.in/gZmnBnw8

What we've been talking about for months... "Employee says company breached duty to spend funds responsibly." "Lawsuit filed in New Jersey seeks class-action status." Read the article: https://lnkd.in/g_hGGnwh MBGH employer members, check out past monthly employer-only roundtable series recordings and summaries. Our August, 2023 roundtable discussion summary includes a statement, "Health care litigation which has employees suing employers hasn’t happened, but it will," with tips on how to prepare. Check out all the past MBGH roundtable discussions here: https://lnkd.in/gbDc3q5a. Join us this Thursday, Feb. 8 from noon-1:15pm (CT) where we will gather to discuss, "Beyond Hospital Transparency: The Urgency of Getting to Fair Price." Learn more and register: https://lnkd.in/gPB6Mcrm #employers #mbghevents #pricetransparency #healthcare #hr #hrbenefits #hospitalfairprice #fairhealthcosts

FOMO alert: Are you missing out on savings because you’re not focused on a low net-cost strategy for pharmacy benefits? This total cost philosophy can help lower net per member per month costs. With employer drug spend going up, it’s worth seeing what the future can look like: http://spr.ly/6042dms5Q

#HRArticle Beyond the test - ethical concerns spark debate on workplace drug testing written by Rhys Evans, Managing Director at ALCO-Safe (Pty) Ltd The growing prevalence of workplace drug testing has ignited a fiery debate, shifting the spotlight beyond the act of testing itself to examine the integrity of results and the fairness of disciplinary repercussions. Read more here: https://lnkd.in/dxWZscUu

LucyRx is “aligned” with AlignRx ideas. Check us out when you need a better PBM

EMPLOYERS ARE GETTING FLEECED BY THEIR PBM Here's a great piece by Wendell Potter. He talks with a Pharmacy industry veteran who explains how PBMS manipluate employers into spending more than they need to or should be for prescription drugs. He addresses issues like the inherent conflict of interests for the BIG 3 and many other PBMs, spread pricing, revenue-sharing agreements, and rebates. I have to give it to the sales/marketing person that came up with pharmacy rebates - hyping the purchase of more expensive drugs over therapeutic equivalents so that the employer is overcharged for a particular drug but can then receive part of the overpayment back as a "rebate". Meanwhile, numerous other middlemen receive thier portion of this overpayment too.. A couple of other greatpoints from the article include: - A lot of money flows between the drug manufacturer and PBM in ways that incentivize the PBM to push that manufacturer’s products. Now we’ve got a direct conflict of interest in that regard. There’s a revenue source coming from the PBM that the client doesn’t have access to that influences everything the PBM does and all the decisions it makes. - You’re trying to DISCOUNT trend in pharmacy costs, but you’re not IMPACTING trend. You’re shaving PENNIES, whereas you’re ignoring where the real DOLLARS are.